Drug Profile
Rituximab biosimilar - Eden Biologics
Alternative Names: JHL 1101Latest Information Update: 23 Dec 2021
Price :
$50
*
At a glance
- Originator JHL Biotech
- Developer Eden Biologics; Sanofi
- Class Antineoplastics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Rheumatoid arthritis
Most Recent Events
- 17 Jan 2020 Discontinued - Phase-I for B-cell lymphoma (Second-line therapy or greater) in China (IV) (JHL Biotech's pipeline - January 2020)
- 17 Jan 2020 Discontinued - Phase-I for Rheumatoid arthritis (Treatment-experienced) in Hungary, Poland, Czech Republic, Bosnia-Herzegovina, Lithuania, Germany, Bulgaria, Ukraine, Russia, Taiwan, United Kingdom (IV) (JHL Biotech's pipeline - January 2020)
- 17 Jan 2020 Discontinued - Phase-III for Diffuse large B cell lymphoma (First-line therapy) in United Kingdom, Czech Republic, Hungary, China (IV) (JHL Biotech's pipeline - January 2020)